Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
RESEARCH TOOLSreports
Adaptimmune Therapeutics (ADAP) Stock Price & Analysis
684 Followers
ADAP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.42 - $2.05
Previous Close$0.99
Volume2.56M
Average Volume (3M)1.97M
Market Cap
$198.77M
Enterprise Value$102.51M
Total Cash (Recent Filing)$146.94M
Total Debt (Recent Filing)$25.23M
Price to Earnings (P/E)-1.9
Beta1.72
Next Earnings
May 06, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding246,825,076
10 Day Avg. Volume1,297,326
30 Day Avg. Volume1,968,064
Standard Deviation0.48
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.49
Price to Sales (P/S)4.04
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda-0.98
Forecast
1Y Price Target
$3.40Price Target Upside288.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Adaptimmune Therapeutics News
Bulls Say, Bears Say
Bulls Say
Commercial StrategyADAP is initially targeting ~6-10 authorized treatment centers for afami-cel, with plans to expand, showing a focused and scalable launch strategy.
Leadership And HiringThe hiring of Ms. Piccina is considered a key step in ADAP's launch preparation for afami-cel, indicating readiness for the upcoming commercial launch.
Regulatory MilestoneFDA acceptance of the BLA for afami-cel sets a clear path for potential product launch.
Bears Say
Collaboration TerminationGenentech collaboration with ADAP has been terminated, affecting future milestone payments.
Financial ForecastADAP's cash runway expectation has been moderately contracted, with potential updates on financial impact forthcoming.
Investor SentimentADAP's stock is underperforming, reflecting investor sentiment negatively impacted by the loss of the Genentech collaboration.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ADAP FAQ
What was Adaptimmune Therapeutics’s price range in the past 12 months?
Adaptimmune Therapeutics lowest stock price was $0.42 and its highest was $2.05 in the past 12 months.
What is Adaptimmune Therapeutics’s market cap?
Currently, no data Available
When is Adaptimmune Therapeutics’s upcoming earnings report date?
Adaptimmune Therapeutics’s upcoming earnings report date is May 06, 2024 which is in 18 days.
How were Adaptimmune Therapeutics’s earnings last quarter?
Adaptimmune Therapeutics released its earnings results on Mar 06, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.165 by $0.125.
Is Adaptimmune Therapeutics overvalued?
According to Wall Street analysts Adaptimmune Therapeutics’s price is currently Undervalued.
Does Adaptimmune Therapeutics pay dividends?
Adaptimmune Therapeutics does not currently pay dividends.
What is Adaptimmune Therapeutics’s EPS estimate?
Adaptimmune Therapeutics’s EPS estimate is -$0.15.
How many shares outstanding does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has 255,561,980 shares outstanding.
What happened to Adaptimmune Therapeutics’s price movement after its last earnings report?
Adaptimmune Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.165. Following the earnings report the stock price went up 17.123%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics?
Among the largest hedge funds holding Adaptimmune Therapeutics’s share is Matrix Capital Management Company, LP. It holds Adaptimmune Therapeutics’s shares valued at 31M.
---
Adaptimmune Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.40 (288.57% Upside)
$3.40 (288.57% Upside)
Blogger Sentiment
Bullish
ADAP Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.99%
12-Months-Change
Fundamentals
Return on Equity
-187.96%
Trailing 12-Months
Asset Growth
-14.08%
Trailing 12-Months
Company Description
Adaptimmune Therapeutics
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
---
ADAP Earnings Call
Q4 2024
0:00 / 0:00
---
ADAP Stock 12 Months Forecast
Average Price Target
$3.40
▲(288.57% Upside)
Technical Analysis
Best Analysts Covering ADAP
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+67.92%
assigned a buy rating last month
Copying Marc Frahm's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +67.92% per trade.
---